Selective Angiotensin II Receptor Antagonists for Hypertension Treatment

OVERVIEW

This invention presents novel peptides and peptide analogs designed to selectively inhibit angiotensin II (Ang II) and its associated signaling pathways, offering a promising approach for hypertension treatment. The peptides, notably PEP7, target specific pathways downstream of the Ang II receptor, potentially reducing adverse effects associated with conventional medications.

BACKGROUND

Hypertension remains a global health challenge, often requiring multiple medications for effective control. Conventional therapies such as angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can lead to adverse effects, impacting patient compliance. This invention addresses the need for novel Ang II inhibitors/receptor antagonists with distinct therapeutic profiles, potentially enhancing efficacy and reducing side effects.

Benefit

• Specific targeting of the Ang II signaling pathway reduces adverse effects associated with conventional medications.
• Potential for improved patient compliance and treatment outcomes due to reduced side effects.
• Offers a new avenue for hypertension treatment with the potential for synergistic effects when combined with existing therapies.

Market Application

• Pharmaceutical Industry: Offers a potentially lucrative opportunity for developing novel hypertension medications with improved therapeutic profiles.
• Healthcare Providers: Presents a promising alternative for patients with hypertension who experience adverse effects from conventional medications.
• Research and Development: Provides a platform for further exploration of selective Ang II receptor antagonists for various cardiovascular conditions.

Publications

US Patent Application Issued - National Phase No. 9,944,677

Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide. Am J Physiol Regul Integr Comp Physiol. 2014 Apr 15;306(8):R619-26. doi: 10.1152/ajpregu.00562.2013.